Strategies to Improve Drug Delivery Across the Blood-brain Barrier

Overview

Journal Clin Pharmacokinet

Specialty Pharmacology

Date 2007 Jun 29

PMID 17596102

Citations 29

Authors

Albertus G de Boer

Pieter J Gaillard

Affiliations

Soon will be listed here.

Abstract

The blood-brain barrier (BBB), together with the blood-cerebrospinal-fluid barrier, protects and regulates the homeostasis of the brain. However, these barriers also limit the transport of small-molecule and, particularly, biopharmaceutical drugs such as proteins, genes and interference RNA to the brain, thereby limiting the treatment of many brain diseases. As a result, various drug delivery and targeting strategies are currently being developed to enhance the transport and distribution of drugs into the brain. In this review, we discuss briefly the biology and physiology of the BBB as the most important barrier for drug transport to the brain and, in more detail, the possibilities for delivering large-molecule drugs, particularly genes, by receptor-mediated nonviral drug delivery to the (human) brain. In addition, the systemic and intracellular pharmacokinetics of nonviral gene delivery, together with targeted brain imaging, are reviewed briefly.

Citing Articles

Towards Symmetric Thioamides: Microwave-Aided Synthesis of Terephthalic Acid Derivatives.

Bak A, Kozik V, Swietlicka A, Baran W, Smolinski A, Zieba A Pharmaceuticals (Basel). 2023; 16(7).

PMID: 37513896 PMC: 10385826. DOI: 10.3390/ph16070984.

Molecular Imaging of Ultrasound-Mediated Blood-Brain Barrier Disruption in a Mouse Orthotopic Glioblastoma Model.

Bastiancich C, Fernandez S, Correard F, Novell A, Larrat B, Guillet B Pharmaceutics. 2022; 14(10).

PMID: 36297663 PMC: 9610067. DOI: 10.3390/pharmaceutics14102227.

Heparin-binding Peptides as Novel Therapies to Stop SARS-CoV-2 Cellular Entry and Infection.

Tavassoly O, Safavi F, Tavassoly I Mol Pharmacol. 2020; 98(5):612-619.

PMID: 32913137 PMC: 7610036. DOI: 10.1124/molpharm.120.000098.

Nanotherapeutics in Neuropathologies: Obstacles, Challenges and Recent Advancements in CNS Targeted Drug Delivery Systems.

Patel V, Chavda V, Shah J Curr Neuropharmacol. 2020; 19(5):693-710.

PMID: 32851949 PMC: 8573747. DOI: 10.2174/1570159X18666200807143526.

Polymeric Nanoparticles for the Treatment of Malignant Gliomas.

Mahmoud B, AlAmri A, McConville C Cancers (Basel). 2020; 12(1).

PMID: 31936740 PMC: 7017235. DOI: 10.3390/cancers12010175.

References

Yew N, Cheng S . Reducing the immunostimulatory activity of CpG-containing plasmid DNA vectors for non-viral gene therapy. Expert Opin Drug Deliv. 2005; 1(1):115-25. DOI: 10.1517/17425247.1.1.115. View

Mangano D, Miao Y, Vuylsteke A, Tudor I, Juneja R, Filipescu D . Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA. 2007; 297(5):471-9. DOI: 10.1001/jama.297.5.471. View

Boeckle S, Fahrmeir J, Roedl W, Ogris M, Wagner E . Melittin analogs with high lytic activity at endosomal pH enhance transfection with purified targeted PEI polyplexes. J Control Release. 2006; 112(2):240-8. DOI: 10.1016/j.jconrel.2006.02.002. View

Moos T, Morgan E . The significance of the mutated divalent metal transporter (DMT1) on iron transport into the Belgrade rat brain. J Neurochem. 2003; 88(1):233-45. DOI: 10.1046/j.1471-4159.2003.02142.x. View

Opanashuk L, Mark R, Porter J, Damm D, Mattson M, Seroogy K . Heparin-binding epidermal growth factor-like growth factor in hippocampus: modulation of expression by seizures and anti-excitotoxic action. J Neurosci. 1998; 19(1):133-46. PMC: 6782387. View

Begley D . Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther. 2004; 104(1):29-45. DOI: 10.1016/j.pharmthera.2004.08.001. View

Bartsch M, Weeke-Klimp A, Meijer D, Scherphof G, Kamps J . Cell-specific targeting of lipid-based carriers for ODN and DNA. J Liposome Res. 2005; 15(1-2):59-92. DOI: 10.1081/lpr-64961. View

von Gersdorff K, Sanders N, Vandenbroucke R, De Smedt S, Wagner E, Ogris M . The internalization route resulting in successful gene expression depends on both cell line and polyethylenimine polyplex type. Mol Ther. 2006; 14(5):745-53. DOI: 10.1016/j.ymthe.2006.07.006. View

Abraham M, Chadha H, Mitchell R . Hydrogen bonding. 33. Factors that influence the distribution of solutes between blood and brain. J Pharm Sci. 1994; 83(9):1257-68. DOI: 10.1002/jps.2600830915. View

10.

Clamme J, Krishnamoorthy G, Mely Y . Intracellular dynamics of the gene delivery vehicle polyethylenimine during transfection: investigation by two-photon fluorescence correlation spectroscopy. Biochim Biophys Acta. 2003; 1617(1-2):52-61. DOI: 10.1016/j.bbamem.2003.09.002. View

11.

Wu D, Yang J, Pardridge W . Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor. J Clin Invest. 1997; 100(7):1804-12. PMC: 508366. DOI: 10.1172/JCI119708. View

12.

Prados M, Schold Jr S, Fine H, Jaeckle K, Hochberg F, Mechtler L . A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. Neuro Oncol. 2003; 5(2):96-103. PMC: 1920676. DOI: 10.1093/neuonc/5.2.96. View

13.

Rousselle C, Clair P, Lefauconnier J, Kaczorek M, Scherrmann J, Temsamani J . New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol Pharmacol. 2000; 57(4):679-86. DOI: 10.1124/mol.57.4.679. View

14.

Ponka P, Lok C . The transferrin receptor: role in health and disease. Int J Biochem Cell Biol. 1999; 31(10):1111-37. DOI: 10.1016/s1357-2725(99)00070-9. View

15.

Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M . Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature. 2004; 432(7014):173-8. DOI: 10.1038/nature03121. View

16.

Bechmann I, Galea I, Perry V . What is the blood-brain barrier (not)?. Trends Immunol. 2006; 28(1):5-11. DOI: 10.1016/j.it.2006.11.007. View

17.

Zhang Y, Han H, Elmquist W, Miller D . Expression of various multidrug resistance-associated protein (MRP) homologues in brain microvessel endothelial cells. Brain Res. 2000; 876(1-2):148-53. DOI: 10.1016/s0006-8993(00)02628-7. View

18.

Lee G, Dallas S, Hong M, Bendayan R . Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. Pharmacol Rev. 2001; 53(4):569-96. View

19.

Ciechanover A . Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol. 2005; 6(1):79-87. DOI: 10.1038/nrm1552. View

20.

Wekerle H . Immune protection of the brain--efficient and delicate. J Infect Dis. 2002; 186 Suppl 2:S140-4. DOI: 10.1086/344937. View